Portal de Periódicos da CAPES

Artigo Acesso aberto Produção Nacional Revisado por pares

BIBTEX RIS

Apolipoprotein A-I Infusions and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels: The AEGIS-II Trial

2024; Oxford University Press; Linguagem: Inglês

10.1093/eurheartj/ehae614

1522-9645

C. Michael Gibson, Danielle Duffy, M. Cecilia Bahit, Gerald Chi, Harvey D. White, Serge Korjian, John H. Alexander, A. Michael Lincoff, Mark Heise, Bronwyn A. Kingwell, José Carlos Nicolau, Renato D. Lópes, Jan H. Cornel, Basil S. Lewis, Dragoş Vinereanu, Shaun G Goodman, Christoph Bode, Philippe Gabríel Steg, Peter Libby, Frank M. Sacks, Kevin R. Bainey, Paul M. Ridker, Kenneth W. Mahaffey, Philip E. Aylward, Stephen J. Nicholls, Stuart J. Pocock, Roxana Mehran, Robert A. Harrington, C. Michael Gibson, John H. Alexander, Philip E. Aylward, Deepak L. Bhatt, Christoph Bode, Shaun G Goodman, Robert A. Harrington, Kenneth W. Mahaffey, A. Michael Lincoff, R. Mehran, Stephen J. Nicholls, Stuart J. Pocock, Paul M. Ridker, Philippe Gabríel Steg, Michał Tendera, Michał Tendera, Pierluigi Tricoci, Pierluigi Tricoci, John H. Alexander, John J.P. Kastelein, A. Michael Lincoff, R. Mehran, Stuart J. Pocock, Philippe Gabríel Steg, Michał Tendera, Pierluigi Tricoci, Cecilia Bahit, Gemma A. Figtree, Kurt Huber, Pascal Vranckx, Renato D. Lópes, José Carlos Nicolau, Nina Gotcheva, Nina N Gotcheva, Juan Carlos Prieto, Miguel Urina‐Triana, Miroslav Solař, Margus Viigimaa, Mika Laine, Gilles Montalescot, Tamaz Shaburishvili, Daniel Duerschmied, Dimitris Tousoulis, Michael Lee, Béla Merkely, Basil S. Lewis, Giuseppe Ambrosio, Ospedale S di Perugia, Satoshi Yasuda, Andrejs Ērglis, Rimvydas Šlapikas, Alan Yean Yip Fong, Jose Luis Leiva Pons, Jan H. Cornel, Harvey D. White, Vibeke Juliebø, Manuel Horna, Jarosław Trębacz, João Morais, Dragoş Vinereanu, Sergey Zenin, Nebojša Tasić, Jack Tan, Jan Murin, Lesley Burgess, Jan Murin, Ángel Cequier, Emil Hagström, Stephan Windecker, Jiunn-Lee Lin, Piyamitr Sritara, Ümit Güray, Vijay Kunadian, Alexander Parkhomenko, Marc P. Bonaca, Thomas J. Povsic, Anthony Gershlick, Amadeu Betriu,

Cancer, Lipids, and Metabolism

In the AEGIS-II trial (NCT03473223), CSL112, a human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity, did not significantly reduce the risk of the primary endpoint through 90 days versus placebo after acute myocardial infarction (MI). Nevertheless, given the well-established relationship between higher low-density lipoprotein cholesterol (LDL-C) and plaque burden, as well as greater risk reductions seen with PCSK9 inhibitors in patients with baseline LDL-C ≥100 mg/dL on statin therapy, the efficacy of CSL112 may be influenced by baseline LDL-C.